{"product_id":"human-lef1-shrna-adenovirus-ad-h-lef1-shrna-bhv21600411","title":"human LEF1 shRNA Adenovirus (Ad-h-LEF1-shRNA)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAd-h-LEF1-shRNA is a replication-defective recombinant Ad5 adenovirus driving short hairpin RNA (shRNA) expression — an shRNA cassette targeting h-LEF1 — under a U6 Pol III promoter for stable, efficient knockdown. Adenoviral delivery enables shRNA-mediated silencing in difficult-to-transfect cell types and in vivo tissues where transient transfection is inefficient.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBackbone:\u003c\/strong\u003e Human adenovirus type 5 (Ad5) with E1 and E3 deleted (dE1\/E3). Replication-incompetent in standard cells; replication-competent helper cells (HEK293) are required for amplification.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter (U6):\u003c\/strong\u003e a Pol III promoter that drives short non-coding RNA (shRNA\/sgRNA) expression.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTransgene:\u003c\/strong\u003e h-LEF1-shRNA (eGFP tag).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiter \u0026amp; format:\u003c\/strong\u003e 1×10\u003csup\u003e10\u003c\/sup\u003e PFU\/ml in storage buffer (DMEM, 2% BSA, 2.5% glycerol or equivalent), supplied as a 200 µL aliquot.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eshRNA cassette:\u003c\/strong\u003e Pol III-driven hairpin expression for stable knockdown; the transcribed shRNA is processed into a functional siRNA by Dicer and loaded into RISC for sequence-specific mRNA cleavage or translational repression.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eThis is an pre-made gene silencing adenovirus that expresses a shRNA to knockdown human LEF1 gene. The shRNA expression is driven by an U6 promoter.\u003c\/p\u003e\u003cp\u003eThe knockdown of this human gene was validated by qPCR in MDA-MB 231 cells.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eUsed in oncology research to model gain-of-function or loss-of-function alterations in tumor-relevant pathways.\u003c\/li\u003e\n\u003cli\u003eAdenoviral delivery enables high-efficiency transduction of cancer cell lines and primary tumor cells.\u003c\/li\u003e\n\u003cli\u003eDecision-relevant for researchers studying Wnt\/β-Catenin Pathway.\u003c\/li\u003e\n\u003cli\u003eAdenovirus-mediated delivery is well-established in primary cells, organoids, and small-animal models.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eLoss-of-function knockdown in cell lines and primary cells.\u003c\/li\u003e\n\u003cli\u003ePathway interrogation paired with matched scrambled-shRNA controls.\u003c\/li\u003e\n\u003cli\u003eIn vivo knockdown via tissue-targeted intravenous or local delivery.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConfirm target depletion at the protein level (Western blot) in addition to mRNA-level (qPCR), and verify with a non-targeting scrambled-shRNA control.\u003c\/li\u003e\n\u003cli\u003eAdenoviral delivery is episomal and non-integrating; expression dilutes with cell division and typically lasts 1–2 weeks in dividing cells (longer in non-dividing cells such as hepatocytes, neurons, and cardiomyocytes).\u003c\/li\u003e\n\u003cli\u003ePre-existing anti-Ad5 neutralizing antibodies are common in human and primate hosts and can reduce in vivo transduction; this is less relevant in inbred laboratory mouse strains.\u003c\/li\u003e\n\u003cli\u003eMOI optimization is essential — over-dosing can cause cytopathic effects; under-dosing yields incomplete transduction. A 3–5× MOI titration in your specific cell or animal model is recommended.\u003c\/li\u003e\n\u003cli\u003eReplication-defective Ad5 vectors are typically handled at BSL-2; consult your institutional biosafety officer for specific transgenes and routes of use.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal):\n  - NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n  - UniProt: https:\/\/www.uniprot.org\/\n  - Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009; 90:1–20.\n  - Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12 Suppl 1:S18–27.\n  - Brummelkamp TR et al. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550–3.\n  - Vendor reference: https:\/\/www.vectorbiolabs.com\/product\/1845-human-lef1-shrna-adenovirus\/\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"1x10^10 PFU\/ml \/ 200 µL","offer_id":53286501319021,"sku":"1845","price":995.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/human-lef1-shrna-adenovirus-ad-h-lef1-shrna-bhv21600411","provider":"BioHippo","version":"1.0","type":"link"}